Nektar Therapeutics (LON:0UNL)
51.28
+1.66 (3.35%)
At close: Sep 17, 2025
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.18M USD in the quarter ending June 30, 2025, a decrease of -52.42%. This brings the company's revenue in the last twelve months to $74.93M, down -19.56% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$74.93M
Revenue Growth
-19.56%
P/S Ratio
12.71
Revenue / Employee
$1.23M
Employees
61
Market Cap
695.26M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Nektar Therapeutics News
- 8 days ago - Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 - PRNewsWire
- 12 days ago - Nektar Therapeutics (NKTR) Surges on Rival's Disappointing Results - GuruFocus
- 12 days ago - Why Nektar Therapeutics Rippled Higher This Week - The Motley Fool
- 13 days ago - Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus
- 13 days ago - What's Going On With Nektar Therapeutics Stock On Thursday? - Benzinga
- 13 days ago - What's Going On With Nektar Therapeutics Stock On Thursday? - Benzinga
- 14 days ago - Nektar Therapeutics to Participate in Two Investor Conferences in September - PRNewsWire
- 26 days ago - Nektar Therapeutics: Fairly Valued, High-Quality Biotech With Multiple Near-Term Catalysts - Seeking Alpha